Blood test could replace gadolinium scans for MS monitoring

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with RRMS according to 2024 McDonald's criteria. * Less than 10 years from disease onset. * Active RRMS (EDA) observed during the last 24 months: relapse and/or NELs and/or CELs as compared to a previous MRI performed within 24 months (± 3 months). * Current MET (IFN, GA, TE, fumarates) for less than 24 months. * Standard MRI follow-up scan performed less than 90 days before inclusion. * Clinically stable disease for at least 30 days. * Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL. * For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial. * Patients able to adhere to the study visit schedule. * Patient must have signed and given the consent. * Patient affiliated or beneficiary of a health insurance plan. Exclusion Criteria: * Pregnant or breastfeeding woman. * Patient unable to perform brain and/or spinal cord MRI scans. * Patient not willing to perform monthly blood punctures. * Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone). * Patient with a relapse within 6 months before inclusion. * Patient with CELs within 3 months before inclusion. * Patient with progressive MS. * Patient unable to sign the consent. * It is impossible to correctly inform the patient. * Patient already participating in therapeutic research or in an exclusion period. The exclusion period corresponds to five half-lives (t1/2) of the experimental drug. * Patient under judicial protection, or is an adult under guardianship. * Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control for the duration of the trial.